BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38677772)

  • 1. Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal Cancer Cell Lines Regardless of HPV Status.
    Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
    Anticancer Res; 2024 May; 44(5):1863-1876. PubMed ID: 38677772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors.
    Kostopoulou ON; Zupancic M; Pont M; Papin E; Lukoseviciute M; Mikelarena BA; Holzhauser S; Dalianis T
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations.
    Holzhauser S; Wild N; Zupancic M; Ursu RG; Bersani C; Näsman A; Kostopoulou ON; Dalianis T
    Front Oncol; 2021; 11():640490. PubMed ID: 34046344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma.
    Kawakami H; Okamoto I; Terao K; Sakai K; Suzuki M; Ueda S; Tanaka K; Kuwata K; Morita Y; Ono K; Nishio K; Nishimura Y; Doi K; Nakagawa K
    Cancer Med; 2013 Dec; 2(6):933-41. PubMed ID: 24403267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited.
    Byskata K; Lukoseviciute M; Tuti F; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus.
    Pirotte EF; Holzhauser S; Owens D; Quine S; Al-Hussaini A; Christian AD; Giles PJ; Man ST; Evans M; Powell NG
    PLoS One; 2018; 13(12):e0207934. PubMed ID: 30543656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells.
    Lindsay C; Kostiuk M; Conrad D; O'Connell DA; Harris J; Seikaly H; Biron VL
    Mol Carcinog; 2019 Nov; 58(11):1946-1959. PubMed ID: 31338907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy alone as a possible de-intensified treatment for human papillomavirus-related locally advanced oropharyngeal squamous cell carcinoma.
    Yamamoto Y; Takemoto N; Michiba T; Seo Y; Isohashi F; Otani K; Suzuki M; Fujii T; Yoshii T; Mitani K; Yasui T; Cho H; Tomita Y; Morii E; Teshima T; Ogawa K; Inohara H
    Int J Clin Oncol; 2019 Jun; 24(6):640-648. PubMed ID: 30694402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
    Sewell A; Brown B; Biktasova A; Mills GB; Lu Y; Tyson DR; Issaeva N; Yarbrough WG
    Clin Cancer Res; 2014 May; 20(9):2300-11. PubMed ID: 24599934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
    Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Holzhauser S; Kostopoulou ON; Ohmayer A; Lange BKA; Ramqvist T; Andonova T; Bersani C; Wickström M; Dalianis T
    Oncol Lett; 2019 Dec; 18(6):6249-6260. PubMed ID: 31788102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
    Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickström M; Kostopoulou ON; Dalianis T
    Int J Oncol; 2021 Feb; 58(2):211-225. PubMed ID: 33491755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.
    Fakhry C; Westra WH; Wang SJ; van Zante A; Zhang Y; Rettig E; Yin LX; Ryan WR; Ha PK; Wentz A; Koch W; Richmon JD; Eisele DW; D'Souza G
    Cancer; 2017 May; 123(9):1566-1575. PubMed ID: 28241096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.
    Peraldo-Neia C; Ostano P; Mello-Grand M; Guana F; Gregnanin I; Boschi D; Oliaro-Bosso S; Pippione AC; Carenzo A; De Cecco L; Cavalieri S; Micali A; Perrone F; Averono G; Bagnasacco P; Dosdegani R; Masini L; Krengli M; Aluffi-Valletti P; Valente G; Chiorino G
    Cell Oncol (Dordr); 2021 Apr; 44(2):357-372. PubMed ID: 33211282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma.
    Kondo S; Hirakawa H; Ikegami T; Uehara T; Agena S; Uezato J; Kinjyo H; Kise N; Yamashita Y; Tanaka K; Hasegawa N; Kiyuna A; Maeda H; Suzuki M; Gahana A
    BMC Cancer; 2021 Jan; 21(1):87. PubMed ID: 33482765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical complete response on treatment outcomes in patients with locally advanced HPV-negative oropharyngeal squamous cell carcinoma.
    De Felice F; Musio D; Abate G; Moscarelli E; Bulzonetti N; Tombolini V
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):477-483. PubMed ID: 31686249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer.
    Idris S; Lindsay C; Kostiuk M; Andrews C; Côté DW; O'Connell DA; Harris J; Seikaly H; Biron VL
    J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):54. PubMed ID: 27793210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma.
    Haft S; Ren S; Xu G; Mark A; Fisch K; Guo TW; Khan Z; Pang J; Ando M; Liu C; Sakai A; Fukusumi T; Califano JA
    Cancer; 2019 Jul; 125(14):2423-2434. PubMed ID: 30933315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.